View the Latest: Heart Disease
Filter
-
-
Heart Disease Deaths and Death Rates per 100,000 Population by Race/Ethnicity
State Health Facts Indicator -
-
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use
Poll FindingAbout one in eight adults say that they are currently taking a GLP-1 drug either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern. Few adults think it is likely their prescription costs will go down as a result of recently announced Trump administration policies.
-
Where Americans Saw Information About Tax and Budget Legislation on Social Media, and False Measles Narratives Target Immigrants — The Monitor
FeatureThis volume shares findings from KFF’s latest poll on how the public encountered information about the recently passed tax and budget legislation; misleading narratives blaming undocumented immigrants for the current measles outbreak; misrepresentations of vaccine safety systems; claims that climate change isn’t real following deadly Texas flooding; and confusion around statins for preventing heart disease.
-
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
FeatureKFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
-
An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk
News ReleaseIn a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients.
-
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity
Issue BriefThe FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese - a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from covering drugs used for obesity. This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.
-
COVID-19 Now Leading Cause of Death in the United States
FeatureIn January 2021, the number of deaths from COVID-19 increased so rapidly that it has clearly become the number one cause of death in the U.S., with an average of more than 3,000 people per day dying of COVID-19 in the U.S. as of Jan. 26. Learn more in this Chart of the Week from the Peterson-KFF Health System Tracker.
-
What Do We Know about Cardiovascular Disease Spending and Outcomes in the United States?
FeatureAlthough mortality rates for cardiovascular disease have fallen dramatically over the past three decades, heart disease remains the leading cause of death in the United States. This slideshow explores the prevalence, disease burden, disparities, outcomes, care, and costs of cardiovascular disease in the United States.